SCHEMBL14677199

SCHEMBL14677199

CC(C)(NS(=O)(=O)Cc1ccc(Cl)c(Cl)c1)C(=O)NC1C2CC3CC(C2)CC1C3

nearest known ligand 0.47

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 15/20 0.47
▸ CNR2 P34972 2/20 0.41
▸ CNR1 P21554 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14676550 0.88 HSD11B1 (0.52) HSD11B1CNR2
SCHEMBL14680509 0.83 HSD11B1 (0.50) HSD11B1
SCHEMBL14676947 0.83 HSD11B1 (0.50) HSD11B1
SCHEMBL14676294 0.82 HSD11B1 (0.50) HSD11B1
SCHEMBL14676015 0.82 HSD11B1 (0.43) HSD11B1
SCHEMBL14675952 0.81 HSD11B1 (0.57) HSD11B1
SCHEMBL14680803 0.81 HSD11B1 (0.57) HSD11B1
SCHEMBL14676588 0.77 HSD11B1 (0.73) HSD11B1
SCHEMBL14677077 0.76 S100A9 (0.44) —
SCHEMBL14676308 0.76 HSD11B1 (0.55) HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9073830-B2 Compound for inhibiting 11β-hydroxy steroid dehydrogenase 1, and a pharmaceutical composition comprising the same HYUNDAI PHARM CO., LTD. (KR) 2015-07-07 — — US disclosed
US-9073830-B2 Compound for inhibiting 11β-hydroxy steroid dehydrogenase 1, and a pharmaceutical composition comprising the same HYUNDAI PHARM CO., LTD. (KR) 2015-07-07 — — US disclosed
US-20140206875-A1 A COMPOUND FOR INHIBITING 11B-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HYUNDAI PHARM CO., LTD. (KR) 2014-07-24 — — US disclosed
US-20140206875-A1 A COMPOUND FOR INHIBITING 11B-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HYUNDAI PHARM CO., LTD. (KR) 2014-07-24 — — US disclosed
WO-2013019091-A2 A COMPOUND FOR INHIBITING 11β-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HYUNDAI PHARM CO., LTD. (KR) 2013-02-07 — — WO disclosed
WO-2013019091-A2 A COMPOUND FOR INHIBITING 11β-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HYUNDAI PHARM CO., LTD. (KR) 2013-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140206875-A1 A COMPOUND FOR INHIBITING 11B-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HSD11B1, HSD11B2, HSD17B1 HSD11B1 1/4885CNR2 4706/4885CNR1 4127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback